Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 3/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | APEX1 | P27695 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16039148 | 1.00 | MEN1 (0.69) | MEN1KMT2ASMN1; SMN2GAATSHR | |
| SCHEMBL10641570 | 0.87 | MEN1 (0.71) | MEN1KMT2ASMN1; SMN2GAATSHR | |
| SCHEMBL29260878 | 0.84 | MEN1 (0.53) | MEN1KMT2ASMN1; SMN2GAATSHR | |
| SCHEMBL28386372 | 0.84 | MEN1 (0.66) | MEN1KMT2ASMN1; SMN2TSHRHSD17B10 | |
| SCHEMBL10431530 | 0.83 | MEN1 (0.69) | MEN1KMT2ASMN1; SMN2GAATSHR | |
| SCHEMBL26033225 | 0.83 | MEN1 (0.69) | MEN1KMT2ASMN1; SMN2GAATSHR | |
| SCHEMBL26032798 | 0.82 | MEN1 (0.51) | MEN1KMT2ASMN1; SMN2GAATSHR | |
| SCHEMBL16090941 | 0.82 | MEN1 (0.46) | MEN1KMT2ASMN1; SMN2GAATSHR | |
| SCHEMBL29409695 | 0.81 | MEN1 (0.66) | MEN1KMT2ASMN1; SMN2GAATSHR | |
| SCHEMBL2033572 | 0.81 | MEN1 (0.66) | MEN1KMT2ASMN1; SMN2GAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4230264-B1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DESEASES | ALKERMES PHARMA IRELAND LTD (IE) | 2026-01-28 | — | — | EP | disclosed |
| EP-2970101-B2 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DESEASES | ALKERMES PHARMA IRELAND LTD (IE) | 2025-09-03 | — | — | EP | disclosed |
| US-20250127747-A1 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2025-04-24 | — | — | US | disclosed |
| US-20250057770-A1 | Monomethylfumarate Prodrug Compositions | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2025-02-20 | — | — | US | disclosed |
| US-12076306-B2 | Prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2024-09-03 | — | — | US | disclosed |
| US-20240024275-A1 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2024-01-25 | — | — | US | disclosed |
| US-20240024275-A1 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2024-01-25 | — | — | US | disclosed |
| US-20240024275-A1 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2024-01-25 | — | — | US | disclosed |
| EP-4230264-A2 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DESEASES | Alkermes Pharma Ireland Limited (IE) | 2023-08-23 | — | — | EP | disclosed |
| EP-4230264-A2 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DESEASES | Alkermes Pharma Ireland Limited (IE) | 2023-08-23 | — | — | EP | disclosed |
| US-9505776-B2 | Prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2016-11-29 | — | — | US | disclosed |
| US-9505776-B2 | Prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2016-11-29 | — | — | US | disclosed |
| US-9505776-B2 | Prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2016-11-29 | — | — | US | disclosed |
| US-20160228376-A1 | MONOMETHYLFUMARATE PRODRUG COMPOSITIONS | MORGAN STANLEY SENIOR FUNDING, INC. | 2016-08-11 | — | — | US | disclosed |
| US-20160228376-A1 | MONOMETHYLFUMARATE PRODRUG COMPOSITIONS | MORGAN STANLEY SENIOR FUNDING, INC. | 2016-08-11 | — | — | US | disclosed |
| US-20160228376-A1 | MONOMETHYLFUMARATE PRODRUG COMPOSITIONS | MORGAN STANLEY SENIOR FUNDING, INC. | 2016-08-11 | — | — | US | disclosed |
| WO-2014152494-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DESEASES | ALKERMES PHARMA IRELAND LIMITED (IE) | 2014-09-25 | — | — | WO | disclosed |
| US-20140275048-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | ALKERMES PHARMA IRELAND LIMITED (IE) | 2014-09-18 | — | — | US | disclosed |
| US-20140275048-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | ALKERMES PHARMA IRELAND LIMITED (IE) | 2014-09-18 | — | — | US | disclosed |
| US-20140275048-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | ALKERMES PHARMA IRELAND LIMITED (IE) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275048-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | FH, FAH, GLS2 | MEN1 1301/4885KMT2A 2595/4885SMN1; SMN2 1861/4885 |
| US-20240024275-A1 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | FH, FAH, GLS2 | MEN1 1301/4885KMT2A 2595/4885SMN1; SMN2 1861/4885 |
| US-20250057770-A1 | Monomethylfumarate Prodrug Compositions | DHFR, FPGS, G6PD | MEN1 535/4885KMT2A 1636/4885SMN1; SMN2 69/4885 |
| US-12076306-B2 | Prodrugs of fumarates and their use in treating various diseases | FH, FAH, GLS2 | MEN1 1301/4885KMT2A 2595/4885SMN1; SMN2 1861/4885 |
| US-20160228376-A1 | MONOMETHYLFUMARATE PRODRUG COMPOSITIONS | DHFR, FPGS, G6PD | MEN1 535/4885KMT2A 1636/4885SMN1; SMN2 69/4885 |
| US-20250127747-A1 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | FH, FAH, GLS2 | MEN1 1301/4885KMT2A 2595/4885SMN1; SMN2 1861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.